期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

^(18)F-FLT PET/CT在肿瘤诊断中的应用 被引量：3

Application of ^(18)F-fluorothymidine PET/CT in diagnosis of tumor
暂未订购
导出
摘要 在PET及PET/CT的应用中,人们逐渐发现仅使用18F-氟脱氧葡萄糖(18F-FDG)作为示踪剂是远远不够的。细胞增殖显像剂18F-氟脱氧胸苷(18F-FLT)是一种新型的示踪剂,本文就18F-FLT在肿瘤诊断、分期及疗效评价方面进行综述。 18F fluorodeoxyglucose, as a kind of tracer, has its limitations in positron emission tomography/computed tomography （PET/CT）. 18F fluorothymidine （18 F-FLT） is a kind of new tracer. The value of 18 F-FLT in diagnosis of tumor, tumor staging and assessment of therapeutic effects was reviewed in this article.
作者 刘婧慧 冯惠茹
机构地区 北京军区总医院核医学科
出处 《中国介入影像与治疗学》 CSCD 2009年第4期388-391,共4页 Chinese Journal of Interventional Imaging and Therapy
关键词 体层摄影术 发射型计算机 细胞增殖 脱氧葡萄糖 Tomography, emission computer Prollferation Deoxylucose
分类号 R730.4 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1陈钊,郑容,吴宁.^(18)F-FDG PET-CT的主要局限性和相应处理措施[J].中国医学影像技术,2006,22(2):320-323. 被引量：12
  • 2Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3 deoxy-3-is F fluorothymidine (^18F-FLT) as a proliferation ima-ging tracer inhumans: correlation of [^18 F3 FLT uptake by positron emissiontomography with Ki 67 immunohistochemistry and flow cytometryin human lung tumors. Clin Cancer Res, 2002,8(11): 3315-3323.
  • 3Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with ^18 F fluorothymidine and ^18 F-fluorodeoxyglueose-pos- itron emission tomography. Chest, 2006,129(2) :393-401.
  • 4Turcotte E, Wiens LW, Grierson JR, et al. Toxicology evaluation of radiotracer doses of 3' deoxy 3'-[^18 F] fluorothymidine (is FFLT) for human PET imaging: laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med, 2007,7(3) :3.
  • 5Saga T, Kawashima H, Araki N, et al. Evaluation of primary brain tumors with FLT PET: usefulness and limitations. Clin Nucl Med, 2006,31(12) :774-780.
  • 6Chen DL, Dehdashti F. Advances in positron emission tomographic imaging of lung cancer. Proc Am Thorac Soc, 2005, 2 (6) :541-544.
  • 7Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: ^18F FLT versus ^18F-FDG. J Nucl Med, 2003,44(9):1426- 1431.
  • 8Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with ^18 F fluorothymidine and ^18 F fluorodeoxyglucose-positron emission tomography. Chest, 2006, 129(2) :393 401.
  • 9van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of ^18F-FLT PET and ^18 F FDG PET in esophageal cancer. J Nucl Med, 2005,46(3) :400 -404.
  • 10Kameyama R, Yamamoto Y, Izuishi K, et al. Detection of gastric cancer using ^18 F-FLT PET: comparison with 18 F FDG PET. Eur J Nucl Med Mol Imaging, 2008,36(3 ):382-388.

二级参考文献39

  • 1王中秋,卢光明,郑玲,朱虹,常林风,吴江,秦莉萍.PET/CT及其他影像手段对胰腺癌诊断的比较研究[J].医学影像学杂志,2006,16(1):84-87. 被引量：17
  • 2陈英鑫,李苏建,王中秋.胰腺癌多层螺旋CT成像新进展[J].中国医学影像技术,2006,22(11):1767-1770. 被引量：10
  • 3Beyer T, Antoch G, Bockisch A, et al. Optimized intravenous contrast administration for diagnostic whole-body ^18F-FDG PET/CT[J]. J Nucl Med,2005,46(3) :429-435.
  • 4Groves AM, Kayani I, Dickson JC, et al. Oral contrast medium in PET/CT: should you or shouldn't you?[J]. Eur J Nucl Med Mol Imaging, 2005,32(10) : 1160-1166.
  • 5Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation[J]. Radiology, 2004,230(3) :879-885.
  • 6Hausegger K, Reinprecht P, Kau T, et al. Clinical experience with a commercially available negative oral contrast medium in PET/CT[J]. Rofo, 2005,177(6) :796-799.
  • 7Hara T, Kosaka N, Suzuki T, et al. Uptake rates of ^18 F-fluorodeoxyglucose and ^11 C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study[J]. Chest, 2003,124(3) :893-901.
  • 8Truong MT, Erasmus JJ, Munden RF, et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT[J]. AJR, 2004, 183(4) : 1127-1132.
  • 9Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET[J].J Nucl Med, 2003, 44 (11) : 1789-1796.
  • 10Tatsumi M, Engles JM, Ishimori T, et al. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically[J]. J Nucl Med, 2004,45(7):1189-1193.

共引文献25

同被引文献53

  • 1张龙江,祁吉.分子影像学报告基因显像的研究进展[J].中国医学影像技术,2005,21(11):1772-1775. 被引量：7
  • 2徐贤,张金山,马林,蔡幼铨,程流泉,孙非,郭行高.3.0T磁共振全身扩散加权成像的正常表现和初步临床研究[J].中国医学影像技术,2007,23(6):793-796. 被引量：42
  • 3WILLMANN JK, BRUGGEN NV, DINKELBORG LM. Molecular imaging in drug development [ J ]. Nat Rev Drug Discov, 2008, 7(7) : 591 -607.
  • 4HARGREAVES RJ. The role of molecular imaging in drug discovery and development [ J ]. Clin Pharmacol Ther, 2008, 28 (3): 349-353.
  • 5GROSS S, PIWNICA-WORM D. Molecular imaging strategies for drug discovery and development [ J ]. Curr Opin Chem Biol, 2006, 10(4) : 334 -342.
  • 6SHIMON G, DAVID PW. Molecular imaging strategies for drug discovery and development[ J]. Curt Opin Chem Biol, 2006, 10 (4) : 334 -342.
  • 7PAULMURUGAN R, UMEZAWA Y, GAMBHIR SS. Noninva- sive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies [J]. Proc Natl Acad Sci USA. 2002. 99(24): 15608 - 15613.
  • 8SCRIVENS M, BHOGAL N. The use of human cell line reporter gene-based assays in chemical toxicity testing [ J ]. Toxicol In Vitro, 2007, 21(7): 1233- 1240.
  • 9HOFMANN M, GAZDHAR A, WEITZEL T, et al. PET/CT imaging of somatostatln reporter 2 (hsstr2) as reporter gene for gene therapy [ J ]. Nucl Instrum Meth A, 2006, 569 (2) : 509 - 511.
  • 10HABERMANN FA, WUENSCH A, SINOWATZ F, et al. Report genes for embryogenesis research in livestock species[ J]. Theriogenology, 2007, 68 ( 11 ) : 116 - 124.

引证文献3

二级引证文献30

中国介入影像与治疗学
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部